Works matching IS 11732563 AND DT 2024 AND VI 44 AND IP 10
Results: 7
The Economic Burden of Atherosclerotic Cardiovascular Disease in Italy.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 10, p. 739, doi. 10.1007/s40261-024-01365-z
- By:
- Publication type:
- Article
Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 10, p. 789, doi. 10.1007/s40261-024-01396-6
- By:
- Publication type:
- Article
Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 10, p. 761, doi. 10.1007/s40261-024-01394-8
- By:
- Publication type:
- Article
Correction to: AVT04: An Ustekinumab Biosimilar.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Calcipotriol and 5-Fluorouracil Combination Therapy for the Treatment of Actinic Keratosis in the Clinic: A Review Article.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 10, p. 733, doi. 10.1007/s40261-024-01392-w
- By:
- Publication type:
- Article
Comparative Cost-Effectiveness of Atezolizumab Versus Durvalumab as First-Line Combination Treatment with Chemotherapy for Patients with Extensive-Disease Small-Cell Lung Cancer in Japan.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 10, p. 749, doi. 10.1007/s40261-024-01383-x
- By:
- Publication type:
- Article
Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 10, p. 773, doi. 10.1007/s40261-024-01395-7
- By:
- Publication type:
- Article